130.85 -3.00(-2.24%) Date: Jun 27, 4:41PM EDT

Celgene Corporation (CELG): Leerink Raises PT On Crohn's Drug Data, Delays Launch

Leerink Partners analysts expect GED-0301 to hit the markets by the third quarter of 2019

Celgene Corporation (CELG): Crohn's Drug Data Has The Street Divided

Celgene presented early data from an ongoing study testing its experimental Crohn's disease drug

Celgene Corporation (CELG) Psoriatic Molecule Gets Green Signal

The drugmaker has a golden opportunity with the drug’s approval to recoup the revenue decline